Marvel Biosciences Secures $15M Non-Dilutive Funding for Phase I Trial of MB-204
Event summary
- Marvel Biosciences secured $15M in non-dilutive funding from 5 Horizons Ventures for its Phase I trial of MB-204, covering 15% of CRO costs.
- Phase I trial, in collaboration with Novotech, is set to begin in Q2 2026 to evaluate MB-204's safety and pharmacokinetics in healthy subjects.
- MB-204, a novel fluorinated derivative of an FDA-approved adenosine A2A receptor antagonist, targets autism spectrum disorder, Rett syndrome, Fragile X, and depression.
- Company has received additional non-dilutive funding from NRC IRAP and AICE, along with new patents in the U.S. and Japan.
The big picture
Marvel Biosciences' strategic partnership with 5 Horizons Ventures underscores the growing momentum in rare disease and neurodevelopmental disorder treatments. The non-dilutive funding model and collaboration with global CROs highlight a trend toward capital-efficient development in the biotech sector. The company's focus on repurposing known compounds for new indications aligns with broader industry efforts to address unmet medical needs in underserved patient populations.
What we're watching
- Trial Execution
- The pace at which Marvel Biosciences can advance MB-204 through Phase I and into Phase II/III studies, particularly in rare disease indications.
- Regulatory Pathway
- Whether the FDA's framework for rare diseases will accelerate MB-204's development and approval process.
- Capital Efficiency
- How Marvel Biosciences' non-dilutive funding strategy will impact its ability to minimize shareholder dilution while advancing its clinical pipeline.
Our editorial coverage:
Related topics